Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Upadacitinib
Rinvoq
Routinely available
SMC (SMC2361)
29/03/2023
Indication
For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
15mg prolonged-release tablets
Comments
- In line with SMC restriction: For use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs (cDMARDs), given either alone or in combination.
Link to Advice
Advice Published
10/05/2021
SMC Submission Type
Abbreviated
SMC Status
Restricted